KURA (Kura Oncology) Interest Expense : $-1.62 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kura Oncology's interest expense for the three months ended in Dec. 2024 was $ -0.40 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.62 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kura Oncology's Operating Income for the three months ended in Dec. 2024 was $ -22.46 Mil. Kura Oncology's Interest Expense for the three months ended in Dec. 2024 was $ -0.40 Mil. Kura Oncology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kura Oncology Interest Expense Historical Data

The historical data trend for Kura Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology Interest Expense Chart

Kura Oncology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.58

-0.41

-0.23

-1.55

-1.62

Kura Oncology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.39	-0.40	-0.41	-0.41	-0.40

Kura Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.62 Mil.

Kura Oncology (NAS:KURA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kura Oncology's Interest Expense for the three months ended in Dec. 2024 was $-0.40 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-22.46 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $12.11 Mil.

Kura Oncology's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Kura Oncology did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kura Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

KUR:Germany

Address

12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130

Website

https://www.kuraoncology.com

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Executives

Brian T. Powl	officer: Chief Commercial Officer	C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas James Doyle	officer: SVP, Finance & Accounting	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair	officer: Chief Legal Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford	officer: Chief Operating Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale	officer: Chief Medical Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Troy Edward Wilson	director, officer: President and CEO	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thomas Malley	director	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Kirsten Flowers	officer: Chief Commercial Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer	director	42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Marc Grasso	officer: CFO, CBO	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell	officer: Acting Chief Medical Officer	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta	officer: Chief Legal Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Antonio Gualberto	officer: Chief Medical Officer	245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142